Retatrutide's FDA Approval Anticipated for 2026 in Weight Loss Sector | Retatrutide News

Retatrutide is expected to receive FDA approval for weight loss by 2026. This drug is part of Eli Lilly's efforts in the GLP-1 agonist sector.
Market News · October 19, 2026